A palladium-catalyzed chelation-assisted C–H olefination of 2-amino biaryls using readily available vinylsilanes as unactivated alkenes was developed to afford valuable arylated vinylsilanes with exclusive (E)-selectivities.
Synthesis of Ti(iv) complexes of donor-functionalised phenoxy-imine tridentates and their evaluation in ethylene oligomerisation and polymerisation
作者:James A. Suttil、Miranda F. Shaw、David S. McGuinness、Michael G. Gardiner、Stephen J. Evans
DOI:10.1039/c3dt32465f
日期:——
TiCl4(thf)2 to give the mono-ligand complexes 5–7. The solid state structures of compounds 4–6 have been determined. Complexes 5–7 have been tested for their potential as ethylene oligomerisation/polymerisation systems in conjunction with MAO activator and benchmarked against the Mitsui phenoxy-imine trimerisation system IV. While the phenoxy-amine complex 6 shows a propensity for polymer formation, the phenoxy-imine
已经探索了三井化学乙烯三聚系统(IV)的许多类似物,其中一个供体原子已被修饰。因此,一系列单阴离子三齿苯氧基-亚胺的(3-(吨丁基)-2-(OH)-C 6 H ^ 4 Ç N(C(CH 3)2 CH 2 OME)1,3-(金刚烷基基)-2-(OH)-C 6 H ^ 4 ç N(2' - (2'' - (SME)C 6 H ^ 4)-C 6 H ^ 4)2,3-(吨丁基)-2-( OSiMe 3)-C 6 H 4C N(C(CH 3)2 CH 2 OMe)3)或苯氧胺(3,5-二(叔丁基)-2-(OH)-C 6 H 4 CH 2 -N(2'-(2''-(OMe)C 6 H 4)-C 6 H 4)4)已经制备了配体,并与TiCl 4或TiCl 4(thf)2反应生成单配体配合物5-7。已经确定了化合物4-6的固态结构。已对配合物5-7作为乙烯低聚/聚合系统和MAO活化剂的潜力进行了测试,并相对
Biphenyl derivatives
申请人:——
公开号:US20020040060A1
公开(公告)日:2002-04-04
The invention relates to compounds of the formula
1
wherein
R is hydrogen, lower alkyl, lower alkoxy, halogen, amino, —N(R
6
)
2
or trifluoromethyl;
R
1
is hydrogen, lower alkoxy or halogen;
R and R
1
may be together —CH═CH—CH═CH—;
R
2
is halogen, lower alkyl or trifluoromethyl;
R
3
is hydrogen or lower alkyl;
R
4
is hydrogen or a cyclic tertiary amine, optionally substituted by lower alkyl;
R
5
is hydrogen, nitro, amino or —N(R
6
)
2
;
R
6
is hydrogen or lower alkyl;
X is —C(O)N(R
6
)—, —(CH
2
)
n
O—, —(CH
2
)—,—N(R
6
)—, —N(R
6
)C(O)— or —N(R
6
)(CH
2
)
n
—; and
n is I or 2;
and pharmaceutically acceptable acid addition salts thereof.
The compounds of formula I may be used for the treatment of diseases related to the NK-l receptor.